JP2018513107A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513107A5
JP2018513107A5 JP2017542390A JP2017542390A JP2018513107A5 JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5 JP 2017542390 A JP2017542390 A JP 2017542390A JP 2017542390 A JP2017542390 A JP 2017542390A JP 2018513107 A5 JP2018513107 A5 JP 2018513107A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutical composition
disorder
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017542390A
Other languages
English (en)
Japanese (ja)
Other versions
JP6700291B2 (ja
JP2018513107A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/052950 external-priority patent/WO2016128529A1/en
Publication of JP2018513107A publication Critical patent/JP2018513107A/ja
Publication of JP2018513107A5 publication Critical patent/JP2018513107A5/ja
Application granted granted Critical
Publication of JP6700291B2 publication Critical patent/JP6700291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017542390A 2015-02-15 2016-02-12 1−(het)アリールスルホニル−(ピロリジン又はピペリジン)−2−カルボキサミド誘導体、及びtrpa1拮抗薬としてのそれらの使用 Active JP6700291B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/073102 2015-02-15
CN2015073102 2015-02-15
CNPCT/CN2015/076318 2015-04-10
CN2015076318 2015-04-10
CN2016071061 2016-01-15
CNPCT/CN2016/071061 2016-01-15
PCT/EP2016/052950 WO2016128529A1 (en) 2015-02-15 2016-02-12 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists

Publications (3)

Publication Number Publication Date
JP2018513107A JP2018513107A (ja) 2018-05-24
JP2018513107A5 true JP2018513107A5 (enExample) 2019-03-22
JP6700291B2 JP6700291B2 (ja) 2020-05-27

Family

ID=55349845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542390A Active JP6700291B2 (ja) 2015-02-15 2016-02-12 1−(het)アリールスルホニル−(ピロリジン又はピペリジン)−2−カルボキサミド誘導体、及びtrpa1拮抗薬としてのそれらの使用

Country Status (20)

Country Link
US (1) US10179782B2 (enExample)
EP (1) EP3256463B1 (enExample)
JP (1) JP6700291B2 (enExample)
KR (1) KR20170118166A (enExample)
CN (1) CN107922392B (enExample)
AU (1) AU2016217851A1 (enExample)
BR (1) BR112017017052A2 (enExample)
CA (1) CA2975196A1 (enExample)
CL (1) CL2017001987A1 (enExample)
CO (1) CO2017007679A2 (enExample)
CR (1) CR20170367A (enExample)
EA (1) EA033497B1 (enExample)
IL (1) IL253478A0 (enExample)
MX (1) MX2017010300A (enExample)
PE (1) PE20180177A1 (enExample)
PH (1) PH12017501478A1 (enExample)
PT (1) PT3256463T (enExample)
SG (1) SG11201706451TA (enExample)
TW (1) TW201639829A (enExample)
WO (1) WO2016128529A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2861566T1 (sl) 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
PL2900669T3 (pl) 2012-09-25 2020-01-31 F. Hoffmann-La Roche Ag Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
AU2014356583B2 (en) 2013-11-26 2019-02-28 F. Hoffmann-La Roche Ag New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
MA50635A (fr) 2014-03-26 2020-08-12 Hoffmann La Roche Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
US10766860B2 (en) 2015-03-06 2020-09-08 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
MX376835B (es) * 2015-03-06 2025-03-07 Pharmakea Inc Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
JP2018519292A (ja) * 2015-07-01 2018-07-19 ファーマケア,インク. リシルオキシダーゼ様2阻害剤およびその使用
EP3344619B1 (en) 2015-09-04 2020-10-28 H. Hoffnabb-La Roche Ag Phenoxymethyl derivatives
WO2017050747A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag New bicyclic compounds as dual atx/ca inhibitors
AU2016328437A1 (en) 2015-09-24 2018-01-25 F. Hoffmann-La Roche Ag Bicyclic compounds as ATX inhibitors
BR112018006080A2 (pt) 2015-09-24 2018-10-09 F. Hoffmann-La Roche Ag novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
CA3012812A1 (en) 2016-02-05 2017-08-10 Ea Pharma Co., Ltd. Heterocyclic sulfonamide derivative and medicine containing same
CN109476640B (zh) * 2016-07-20 2022-02-25 豪夫迈·罗氏有限公司 双环脯氨酸化合物
EP3487849A1 (en) 2016-07-20 2019-05-29 H. Hoffnabb-La Roche Ag Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
CN109803964A (zh) * 2016-08-12 2019-05-24 豪夫迈·罗氏有限公司 磺酰基吡啶基trp抑制剂
SG11201901999XA (en) 2016-09-07 2019-04-29 Pharmakea Inc Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
KR20230162996A (ko) 2016-09-07 2023-11-29 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
WO2018109155A1 (en) 2016-12-16 2018-06-21 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
KR102515694B1 (ko) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
EP3596060B1 (en) 2017-03-16 2023-09-20 F. Hoffmann-La Roche AG New bicyclic compounds as atx inhibitors
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
KR102678977B1 (ko) 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
TW202000201A (zh) 2018-02-20 2020-01-01 瑞士商赫孚孟拉羅股份公司 製備1-芳基磺醯基-吡咯啶-2-甲醯胺瞬時受體電位通道拮抗劑化合物及其結晶型式之方法
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
WO2020116296A1 (ja) 2018-12-07 2020-06-11 ユニマテック株式会社 含フッ素ピリミジン化合物およびその製造方法
CN110156834A (zh) * 2019-06-05 2019-08-23 镇江市高等专科学校 一种黄色荧光铜(i)配合物及其制备方法和应用
JP7471407B2 (ja) 2020-05-19 2024-04-19 ユニマテック株式会社 含フッ素ピリミジン化合物および含フッ素ピリミジノン化合物
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
MX2023005822A (es) * 2020-11-19 2023-05-31 Acousia Therapeutics Gmbh Composicion de gel no acuoso.
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
WO2023133502A1 (en) * 2022-01-07 2023-07-13 The Johns Hopkins University Treatment and prevention of trigeminal neuralgia
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
PY2501648A (es) 2024-01-12 2025-10-31 Syngenta Crop Protection Ag Nuevos compuestos de carboxamida
WO2025155669A1 (en) * 2024-01-17 2025-07-24 The Jackson Laboratory Trpc3 inhibitors and uses thereof
WO2026008750A1 (en) 2024-07-05 2026-01-08 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141805A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
EP2805718B1 (en) 2012-01-17 2018-04-04 EA Pharma Co., Ltd. Heterocyclic amide derivative and pharmaceutical product containing same
EP2937335A4 (en) * 2012-12-18 2016-09-14 Ea Pharma Co Ltd HETEROCYCLIC AMID DERIVATIVE AND MEDICAMENT THEREWITH
WO2014113671A1 (en) * 2013-01-18 2014-07-24 Cubist Pharmaceuticals, Inc. Inhibiting the transient receptor potential a1 ion channel
US9394308B2 (en) * 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
DK3055302T3 (en) * 2013-10-11 2019-03-18 Hoffmann La Roche Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators
BR112016017317B1 (pt) 2014-01-28 2023-04-11 EA Pharma Co., Ltd Composto, e, uso de um composto

Similar Documents

Publication Publication Date Title
JP2020073529A5 (enExample)
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
JP2018513188A5 (enExample)
JP2017528507A5 (enExample)
JP2020514318A5 (enExample)
TW201615219A (zh) 呼吸系統疾病用藥臨床新應用
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2018521121A5 (enExample)
RU2017114346A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
JP2009510044A5 (enExample)
EA201891931A1 (ru) Новые ингибиторы фосфатидилинозитол-3-киназы гамма
JP2017222722A5 (enExample)
JP2018537507A5 (enExample)
JP2020513032A5 (enExample)
JP2017510607A5 (enExample)
JP2016027060A5 (enExample)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
HRP20210294T1 (hr) Postupci liječenja akutnog bubrežnog oštećenja
JP2019515909A5 (enExample)
JP2017522300A5 (enExample)
JP2017105861A5 (enExample)
JP2019533660A5 (enExample)
JP2015510916A5 (enExample)
JP2015522603A5 (enExample)